Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study.

Chiloiro S, Lanza F, Bianchi A, Schinzari G, Brizi MG, Giampietro A, Rufini V, Inzani F, Giordano A, Rindi G, Pontecorvi A, De Marinis L.

Endocrine. 2018 May;60(2):362-367. doi: 10.1007/s12020-017-1327-0. Epub 2017 May 31.

PMID:
28567607
2.

Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1.

Kornaczewski Jackson ER, Pointon OP, Bohmer R, Burgess JR.

J Clin Endocrinol Metab. 2017 Jun 1;102(6):1926-1933. doi: 10.1210/jc.2016-3865.

PMID:
28323985
3.

Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1-Results From the Dutch MEN1 Study Group.

Pieterman CRC, de Laat JM, Twisk JWR, van Leeuwaarde RS, de Herder WW, Dreijerink KMA, Hermus ARMM, Dekkers OM, van der Horst-Schrivers ANA, Drent ML, Bisschop PH, Havekes B, Borel Rinkes IHM, Vriens MR, Valk GD.

J Clin Endocrinol Metab. 2017 Oct 1;102(10):3795-3805. doi: 10.1210/jc.2017-00372.

PMID:
28938468
4.

Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis.

Pieterman CR, Conemans EB, Dreijerink KM, de Laat JM, Timmers HT, Vriens MR, Valk GD.

Endocr Relat Cancer. 2014 May 6;21(3):R121-42. doi: 10.1530/ERC-13-0482. Print 2014 Jun. Review.

PMID:
24389729
5.

Endoscopic Ultrasound Features of Multiple Endocrine Neoplasia Type 1-Related versus Sporadic Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Study.

Tamagno G, Scherer V, Caimo A, Bergmann SR, Kann PH.

Digestion. 2018;98(2):112-118. doi: 10.1159/000487939. Epub 2018 Apr 26.

PMID:
29698969
6.

PROGNOSTIC FACTORS FOR SURVIVAL OF MEN1 PATIENTS WITH DUODENOPANCREATIC TUMORS METASTATIC TO THE LIVER: RESULTS FROM THE DMSG.

Conemans EB, Nell S, Pieterman CRC, de Herder WW, Dekkers OM, Hermus AR, van der Horst-Schrivers AN, Bisschop PH, Havekes B, Drent ML, Vriens MR, Valk GD.

Endocr Pract. 2017 Jun;23(6):641-648. doi: 10.4158/EP161639.OR. Epub 2017 Feb 22.

PMID:
28225311
7.

Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients.

Qiu W, Christakis I, Silva A, Bassett RL Jr, Cao L, Meng QH, Gardner Grubbs E, Zhao H, Yao JC, Lee JE, Perrier ND.

Clin Endocrinol (Oxf). 2016 Sep;85(3):400-7. doi: 10.1111/cen.13119. Epub 2016 Jun 30.

8.

EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1.

van Asselt SJ, Brouwers AH, van Dullemen HM, van der Jagt EJ, Bongaerts AH, Kema IP, Koopmans KP, Valk GD, Timmers HJ, de Herder WW, Feelders RA, Fockens P, Sluiter WJ, de Vries EG, Links TP.

Gastrointest Endosc. 2015 Jan;81(1):159-167.e2. doi: 10.1016/j.gie.2014.09.037.

PMID:
25527055
9.

Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity.

Garbrecht N, Anlauf M, Schmitt A, Henopp T, Sipos B, Raffel A, Eisenberger CF, Knoefel WT, Pavel M, Fottner C, Musholt TJ, Rinke A, Arnold R, Berndt U, Plöckinger U, Wiedenmann B, Moch H, Heitz PU, Komminoth P, Perren A, Klöppel G.

Endocr Relat Cancer. 2008 Mar;15(1):229-41. doi: 10.1677/ERC-07-0157.

PMID:
18310290
10.

Proliferation rates of multiple endocrine neoplasia type 1 (MEN1)-associated tumors.

Walls GV, Reed AA, Jeyabalan J, Javid M, Hill NR, Harding B, Thakker RV.

Endocrinology. 2012 Nov;153(11):5167-79. doi: 10.1210/en.2012-1675. Epub 2012 Sep 28.

11.

Rupture of small cystic pancreatic neuroendocrine tumor with many microtumors.

Sagami R, Nishikiori H, Ikuyama S, Murakami K.

World J Gastroenterol. 2017 Oct 7;23(37):6911-6919. doi: 10.3748/wjg.v23.i37.6911.

12.

Multiple endocrine neoplasia type 1 syndrome: single centre experience from western India.

Goroshi M, Bandgar T, Lila AR, Jadhav SS, Khare S, Shrikhande SV, Uchino S, Dalvi AN, Shah NS.

Fam Cancer. 2016 Oct;15(4):617-24. doi: 10.1007/s10689-016-9891-7.

PMID:
26905068
13.

Clinical features and prognosis of thymic neuroendocrine tumours associated with multiple endocrine neoplasia type 1: A single-centre study, systematic review and meta-analysis.

Ye L, Wang W, Ospina NS, Jiang L, Christakis I, Lu J, Zhou Y, Zhu W, Cao Y, Wang S, Perrier ND, Young WF Jr, Ning G, Wang W.

Clin Endocrinol (Oxf). 2017 Dec;87(6):706-716. doi: 10.1111/cen.13480. Epub 2017 Oct 16. Review.

PMID:
28940393
14.

Multiple endocrine neoplasia type 1: extensive analysis of a large database of Florentine patients.

Marini F, Giusti F, Brandi ML.

Orphanet J Rare Dis. 2018 Nov 14;13(1):205. doi: 10.1186/s13023-018-0938-8.

15.

Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life.

Gonçalves TD, Toledo RA, Sekiya T, Matuguma SE, Maluf Filho F, Rocha MS, Siqueira SA, Glezer A, Bronstein MD, Pereira MA, Jureidini R, Bacchella T, Machado MC, Toledo SP, Lourenço DM Jr.

J Clin Endocrinol Metab. 2014 Jan;99(1):E89-96. doi: 10.1210/jc.2013-1768. Epub 2013 Dec 20.

PMID:
24178797
16.

Expression of p27Kip1 and p18Ink4c in human multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors.

Conemans EB, Raicu-Ionita GM, Pieterman CRC, Dreijerink KMA, Dekkers OM, Hermus AR, de Herder WW, Drent ML, van der Horst-Schrivers ANA, Havekes B, Bisschop PH, Offerhaus GJ, Borel Rinkes IHM, Valk GD, Timmers HTM, Vriens MR.

J Endocrinol Invest. 2018 Jun;41(6):655-661. doi: 10.1007/s40618-017-0783-y. Epub 2017 Nov 13.

PMID:
29134609
17.

Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in female patients with multiple endocrine neoplasia syndrome type 1?

Qiu W, Christakis I, Stewart AA, Vodopivec DM, Silva-Figueroa A, Chen H, Woodard TL, Halperin DM, Lee JE, Yao JC, Perrier ND.

Clin Endocrinol (Oxf). 2017 Jun;86(6):791-797. doi: 10.1111/cen.13324. Epub 2017 Apr 6.

PMID:
28273369
18.

The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors.

Nuñez JE, Donadio M, Filho DR, Rego JF, Barros M, Formiga MN, Lopez R, Riechelmann R.

J Gastrointest Oncol. 2019 Aug;10(4):645-651. doi: 10.21037/jgo.2019.01.33.

19.

Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study.

Faggiano A, Ferolla P, Grimaldi F, Campana D, Manzoni M, Davì MV, Bianchi A, Valcavi R, Papini E, Giuffrida D, Ferone D, Fanciulli G, Arnaldi G, Franchi GM, Francia G, Fasola G, Crinò L, Pontecorvi A, Tomassetti P, Colao A.

J Endocrinol Invest. 2012 Oct;35(9):817-23. doi: 10.3275/8102. Epub 2011 Nov 9.

PMID:
22080849
20.

Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms.

Görtz B, Roth J, Krähenmann A, de Krijger RR, Muletta-Feurer S, Rütimann K, Saremaslani P, Speel EJ, Heitz PU, Komminoth P.

Am J Pathol. 1999 Feb;154(2):429-36.

Supplemental Content

Support Center